Rathbones Group’s BioNTech BNTX Stock Holding History

Rathbones Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,757	Closed	-$327K	–	612
2024 Q3	$327K	Buy	+2,757	New	+$253K	﹤0.01%	468

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Rathbones Group's BNTX Position: Q4 2024 in Review

Rathbones Group sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 2,757 shares — an estimated $327K sold.

Rathbones Group first reported a position in BNTX in Q3 2024 and held it in 1 quarter. The position peaked at $327K in Q3 2024. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

Rathbones Group reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
Rathbones Group sold 2,757 BioNTech shares in Q4 2024, an estimated $327K.
Rathbones Group first reported a position in BioNTech in Q3 2024 and held it in 1 quarter.
Rathbones Group's BioNTech position peaked at $327K in Q3 2024.
303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on Rathbones Group's 13F filing for Q4 2024, filed 13 Feb 2025.